A Phase 1b open-label, dose-escalation, safety, and pharmacodynamic study of MinnelideTM capsules given in combination with osimertinib in patients with EGFR mutated NSCLC (United States). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.